GlassScriptPhysician profile
Ian M Storch
NPI 1821040734
$165,799.21
in general payments reported to CMS, 2019-2025
50 companies · $89K in 2025
The $89K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $10K · 2021: $10K · 2022: $4,958 · 2023: $4,193 · 2024: $18K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $105K · Food and Beverage: $6,362 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $104,798.34 |
| Food and Beverage | $6,362.16 |
| Education | $113.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $140,574.18 | 2019-2025 | Capsocam Plus, Capsocam Colon |
| Merck Sharp & Dohme LLC | $6,394.30 | 2019-2022 | |
| Abbvie INC. | $3,914.46 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Amgen INC. | $2,497.54 | 2021-2025 | Repatha, Repatha |
| Capsopro Services LLC | $2,400.00 | 2019-2020 | |
| Pentax of America, INC. | $1,500.00 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,053.91 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $986.09 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $909.13 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $743.86 | 2019-2025 | Linzess |
| Pfizer INC. | $589.79 | 2019-2025 | |
| Redhill Biopharma INC. | $547.57 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $329.01 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $309.93 | 2022-2024 | Ibsrela |
| Lilly USA, LLC | $293.49 | 2022-2025 | Omvoh, Zepbound, Jardiance |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,622,511.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Storch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.